Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 936803911
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2015.11.11, US 201562253805 P
RIINA, H. A. et al.: "Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.", Journal of Experimental Therapeutics and Oncology., vol. 8, no. 2, 12 September 2009 (2009-09-12), pages 145-150, XP055383984, (B1)
RICHARD T FRANK ET AL: "Strategies for enhancing antibody delivery to the brain", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1816, no. 2, 3 July 2011 (2011-07-03) , pages 191-198, XP028392590, ISSN: 0304-419X, DOI: 10.1016/J.BBCAN.2011.07.002 [retrieved on 2011-07-08] (B1)
THAKER ASHESH A ET AL: "Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma", INTERNATIONAL JOURNAL OF HYPERTHERMIA,, vol. 28, no. 8, 1 January 2012 (2012-01-01), pages 766-775, XP009512954, ISSN: 1464-5157, DOI: 10.3109/02656736.2012.724517 (B1)
US-A1- 2010 010 394 (B1)
WATANABE R ET AL: "0322: Contrast-Enhanced Ultrasound (CEUS) with Sonazoid in the Assessment of Anti-Angiogenic Effects of Bevacizumab in a Mouse Xenografted Model", ULTRASOUND IN MEDICINE AND BIOLOGY, NEW YORK, NY, US, vol. 35, no. 8, 1 August 2009 (2009-08-01) , page S42, XP026377538, ISSN: 0301-5629 [retrieved on 2009-07-24] (B1)
WO-A1-2012/019146 (B1)
ZHANG HONG ET AL: "Ultrasound-mediated transscleral delivery of Avastin to the posterior segment of rabbit eye in vivo", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPH THALMOLOGY (ARVO); BALTIMORE, MD, USA; MAY 07 -11, 2017, vol. 55, no. 13, 31 March 2014 (2014-03-31), page 1804, XP009512956, ISSN: 0146-0404 (B1)
ANNA G SORACE ET AL: "Molecular ultrasound imaging of tumor response to bevacizumab using a breast cancer animal model", ULTRASONICS SYMPOSIUM (IUS), 2012 IEEE INTERNATIONAL, IEEE, 7 October 2012 (2012-10-07), pages 2306-2308, XP032434625, ISSN: 1948-5719, DOI: 10.1109/ULTSYM.2012.0576 ISBN: 978-1-4673-4561-3 (B1)
Anonymous: "Mechanical index", Wikipedia , 7 May 2019 (2019-05-07), XP002791062, Retrieved from the Internet: URL:https://en.wikipedia.org/wiki/Mechanic al_index [retrieved on 2019-05-07] (B1)
BHOWMIK, A. et al.: "Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors.", BioMed Research International., vol. 2015, 19 March 2015 (2015-03-19), pages 1-20, XP055383981, (B1)
BONNIN PHILIPPE ET AL: "Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin( ) ) in neovascular age-related macular degeneration", ACTA OPHTHAMOLOGICA (ONLINE), WILEY-BLACKWELL MUNKSGAARD, DENMARK, UNITED KINGDOM, UNITED STATES, NETHERLANDS, vol. 88, no. 6, 31 August 2010 (2010-08-31), pages 641-645, XP009512953, ISSN: 1755-3768, DOI: 10.1111/J.1755-3768.2009.01526.X (B1)
CN-A- 103 002 950 (B1)
DENG, C. X.: "Targeted drug delivery across the blood-brain barrier using ultrasound technique.", Ther Deliv., vol. 1, no. 6, 1 December 2010 (2010-12-01), pages 819-848, XP055384046, (B1)
GIL-GIL MIGUEL J ET AL: "Bevacizumab for the treatment of glioblastoma.", CLINICAL MEDICINE INSIGHTS. ONCOLOGY 2013, vol. 7, 2013, pages 123-135, XP002791061, ISSN: 1179-5549 (B1)
HENDRICKS BENJAMIN K ET AL: "Novel delivery methods bypassing the blood-brain and blood-tumor barriers", NEUROSURGICAL FOCUS, AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS, UNITED STATES, vol. 38, no. 3, 28 February 2015 (2015-02-28), pages E10-1, XP009512952, ISSN: 1092-0684, DOI: 10.3171/2015.1.FOCUS14767 (B1)
HOYT K ET AL: "Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model", ULTRASONICS SYMPOSIUM (IUS), 2009 IEEE INTERNATIONAL, IEEE, PISCATAWAY, NJ, USA, 20 September 2009 (2009-09-20), pages 259-262, XP031654501, ISBN: 978-1-4244-4389-5 (B1)
HOYT KENNETH ET AL: "Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks", JOURNAL OF ULTRASOUND IN MEDICINE : OFFICIAL JOURNAL OF THE AMERICAN INSTITUTE OF ULTRASOUND IN MEDICINE ENGLAND APR 2010, JOURNAL OF ULTRASOUND IN MEDICINE : OFFICIAL JOURNAL OF THE AMERICAN INSTITUTE OF ULTRASOUND IN MEDICINE ENGLAND APR 2010, JOUR, vol. 29, no. 4, 31 March 2010 (2010-03-31) , pages 577-585, XP009512955, ISSN: 1550-9613, DOI: 10.7863/JUM.2010.29.4.577 (B1)
LIU HAO-LI ET AL: "Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment.", RADIOLOGY MAY 2010, vol. 255, no. 2, May 2010 (2010-05), pages 415-425, XP002791060, ISSN: 1527-1315 (B1)
LIU, H. L. et al.: "Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment.", Radiology., vol. 281, no. 1, 1 October 2016 (2016-10-01), pages 99-108, XP055541882, DOI: 10.1148/radiol.2016152444 (B1)
RODRIGUEZ A ET AL: "Neurosurgical techniques for disruption of the blood brain barrier for glioblastoma treatment", PHARMACEUTICS,, vol. 7, no. 3, 3 August 2015 (2015-08-03), pages 175-187, XP009512950, ISSN: 1999-4923, DOI: 10.3390/PHARMACEUTICS7030175 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3374024)
|
Utgående
EP Registreringsbrev (3210) (PTEP3374024)
|
Innkommende, AR503513719
Korrespondanse (Hovedbrev inn)
|
Utgående
EP formelle mangler
|
Innkommende, AR501399231
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 9. avg. år (EP) | 2024.11.19 | 3710 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 8. avg. år (EP) | 2023.11.08 | 2550 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 7. avg. år (EP) | 2022.11.08 | 2200 | CPA GLOBAL LIMITED | Betalt og godkjent |
32210743 expand_more expand_less | 2022.08.23 | 5500 | CURO AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|